Background: As benzodiazepines (BZDs) have anxiolytic effects, it
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As benzodiazepines (BZDs) have anxiolytic and sedating effects, it is expected that they influence the stress system. Most studies on the effects of short-term BZD treatment (maximum of 3 months) on the hypothalamicpituitary-adrenal (HPA) axis in human subjects reported a decrease in cortisol levels, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] although some studies reported mixed results. 12, 13 These inconsistencies may be explained by differences in dosages and half-lives of the BZDs used 13 and by disparities in the measurement time points used in the assessments (only predrug and postdrug measurements, 13 at certain time intervals, 6, 8, [10] [11] [12] 14 or for a full circadian cycle 1, 2, 5 ). Differences in patient groups, 12, 13 and measurements of basal versus stress-provoked cortisol levels may also influence the results. 3, 13 In general, the studies measured plasma cortisol levels [1] [2] [3] 5, 6, 9, 11, 13 or urinary free cortisol as measures of HPA axis activity. 4 Associations between BZD use and dexamethasone suppression have only been investigated in 1 study and no clear effect of BZD use on dexamethasone suppression was observed. 14 A few studies found that the cortisol decrease in response to BZD treatment was followed by a return to baseline cortisol levels within only a few hours, despite persisting high plasma drug levels, [15] [16] [17] suggesting fast development of tolerance to the stress-axis-suppressing effects of
BZDs. In contrast, other studies did report significant cortisol reductions in 24h, overnight and daytime means, 1 suggesting that tolerance does not develop as rapidly.
Tolerance to the effects of BZDs as a consequence of chronic use (>3 months) has been extensively discussed in previous studies. 18, 19 In related research on the therapeutic effects of BZDs, several authors reported that tolerance was developed to only the cognitive and psychomotor effects and not to the anxiolytic effects of chronic BZD treatment, 19 whereas others found decreasing anxiolytic efficacy as well when treatment exceeded a few weeks. 18 Most studies on the effects of 136 | CHAPTER 6
BZDs on cortisol levels found that cortisol suppression was maintained for up to 3 months of use. 1, 2, 4, 9, 12 There was only 1 small cross-sectional study investigating longterm BZD use (> 3 months). 20 The authors found that long-term users have similar baseline cortisol levels as nonusers, indicating that BZDs do not maintain their cortisol-suppressing effects during longer-term use.
In contrast, an additional dosage of BZDs (on top of the BZD dosage that chronic users took daily) still affected the HPA axis after chronic use.
However, comparison groups were small, no measurement of the whole circadian rhythm was conducted, and no dexamethasone challenge test was applied. 20 In this paper, we examine the effects of chronic BZD use on various salivary cortisol measures (cortisol awakening response, diurnal slope, evening cortisol level and suppression after oral dexamethasone administration). In addition, we explore the effects of dosage, duration of use, and level of dependence. The study was carried out on data from 1531 subjects with a lifetime diagnosis of anxiety and / or depression participating in the Netherlands Study of Depression and Anxiety (NESDA).
MAteriALs AND MetHoDs subjects
Subjects participated in the baseline assessment of NESDA, an 8-year longitudinal cohort study of 2981 respondents aged 18 to 65 years. 21 Subjects were recruited from the community, general practice and specialized mental health care institutions throughout the Netherlands.
Subjects completed a medical exam, an in-person interview, saliva collection and several questionnaires. The study protocol was approved by the Ethical Review Board of each participating center and all subjects signed an informed consent at the baseline assessment.
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To investigate the associations between BZD use and salivary cortisol indicators, 3 groups were defined: subjects who reported daily BZD use in the month prior to the baseline interview ("daily BZD users", n=176), subjects who used BZDs on an infrequent basis in the previous month ("infrequent BZD users", n=264) and those reporting no use of BZDs in the last month ("nonusers", n=1854 
salivary cortisol
The respondents were asked to collect saliva samples at home on a regular, preferably working day, shortly after the baseline interview by using Salivettes (Sarstedt AG und Co, Nürmbrecht, Germany). 28 The median time between the interview and saliva sampling was 9 days Switzerland) was used to measure cortisol levels at a functional detection limit of 2.0 nmol/l. 29 Intraassay and interassay variability coefficients in the measuring range were less than 10%. Assays were repeated if cortisol levels were very high (> 80 nmol/L) or very low (< 1 nmol/L) (n=128).
All very high samples remained high in the second measurement, and the mean of the 2 measured values was used in further analyses. In 80% of the very low samples, the repeated cortisol value was within the reference range and was used for analysis. In cases where the second measurement was also very low, the mean of the samples was used. Data cleaning was performed by excluding cortisol values more than 2 SDs above the mean. 28 Four cortisol measures were derived: the CAR, diurnal slope, evening cortisol and cortisol suppression on the DST. 28 140 | CHAPTER 6
Cortisol Awakening Response (CAR)
The CAR was calculated from 4 sampling points: T1, T2, T3, and T4. In our study, it was calculated by analysis of T1 to T4 with Linear Mixed Models (LMM) and 2 aggregate indicators: area under the curve with respect to the ground (AUCg) and with respect to the increase (AUCi) according to Pruessner's formulas. 30 The AUCg is an estimate of the total cortisol secretion and predicts mean cortisol levels throughout the day, and the AUCi is a measure of the dynamics of the CAR, related to the sensitivity of the system and emphasizing changes over time. 28, 30 For the AUC analyses, a minimum of 3 samples were required. For those with 1 missing cortisol value (n=84), the fourth was imputed using linear regression analyses with information on the other available 3 cortisol values, gender, age, awakening time and smoking status.
Diurnal Slope and Evening Cortisol
As cortisol levels at 10 PM (T5) and 11PM (T6) were correlated (r=0.73, P < 0.01), evening cortisol was defined as the average of the 2 values (T5 and T6) or by one of the 2 if only one was available. Diurnal slope was calculated by subtracting the evening cortisol level (as calculated earlier) from the cortisol level at T1 and dividing it by the time in hours between the 2 samples, resulting in the change over time of cortisol throughout the day, calculated per hour.
28,31

Dexamethasone Suppression Test (DST)
In addition to the cortisol level at awakening after dexamethasone ingestion (T7), a cortisol suppression ratio was calculated by dividing the cortisol value at awakening on day 1 (T1) by the post-dexamethasone cortisol value at awakening on day 2 (T7). Lower post-dexamethasone cortisol levels (T7) and higher DST ratios (ie, a larger difference between T1 and T7) indicate a greater cortisol-suppressing effect of dexamethasone.
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Covariates
As associations between sociodemographics (gender, age, education, and North-European ancestry), sampling factors (awakening time, work status, weekday, season, and sleep duration) and health indicators (smoking, physical activity) on salivary cortisol variables have been described previously, 32 these identified determinants were considered as covariates.
Comorbidity of anxiety and depression as well as antidepressant use have been found to be associated with salivary cortisol levels in previous research in this study sample, 28 and numbers of antidepressant use and comorbidity differed between BZD groups (Table 1) . Therefore, comorbidity and antidepressant use were also included as covariates. Table 2 .
Differences in AUCg, AUCi, diurnal slope, evening cortisol, T7, and DST across groups were analyzed using analysis of covariance (ANCOVA), covariates. The other BZDs were not included in these analyses as group numbers were to small (n<15). Oxazepam was used as reference group.
Statistical significance was inferred at P < 0.05. All statistical analyses were conducted using SPSS for Windows, version 16.0 (SPSS, Chicago, Ill).
resULts
Characteristics of the 3 BZD user groups are presented in Table 1 . BZD users were older, less educated, more often diagnosed with a comorbid disorder, and more likely to use antidepressants as compared to nonusers. Only 17.9% of subjects were short-term users (≤3 months), and the remaining 82.1% were long-term users (> 3 months). The median duration of use was 35.5 months (25th -75th percentile: 5-96). Although the group of short-term users was too small (n = 48) to be analyzed separately, exclusion of these subjects did not affect our main results (data not shown). The median daily dosage of BZDs used was 1.0 mg (25th -75th percentile: 0.2 -2.0) of diazepam equivalents for infrequent users and 6.0 mg (25th -75th percentile: 3.2 -13.9) of diazepam equivalents for daily users. Crude saliva levels (T1-T4 and T7) did not differ between groups (Table 2) .
cortisol Awakening response
Overall, 71.5 % of respondents showed an increase in cortisol in the first hour after awakening, with a mean increase of 6.6 nmol/L (or 53.5%). No significant effects were found for any of the crude CAR analyses (Table 2) .
Adjusted CAR results showed that daily users and infrequent users did not differ on overall cortisol levels from nonusers, reflected by analysis of AUCg (P=0.09 for daily users vs nonusers and P=0.74 or infrequent users vs nonusers; 
Diurnal slope
No significant effects were found for crude or adjusted diurnal slope analyses (daily users vs non users: P=0.79).
evening cortisol Level
Unadjusted evening cortisol levels did not differ between groups (Table   2 ). After adjustment, evening cortisol was significantly lower in daily 
Dexamethasone suppression test
The unadjusted cortisol suppression ratio was significantly lower in daily users as compared to nonusers (P=0.049, effect size, 0.08, Table 2 ) which indicates increased nonsuppression after dexamethasone ingestion in the daily user group. After adjustment, however, cortisol suppression ratios (P=0.71) and T7 levels (P=0.46) did not differ between groups. Infrequent users also did not differ from nonusers on either of the cortisol indicators (P=0.46 for cortisol suppression ratio and P=0.31 for T7). Table 3 reports the results of additional analyses on specific associations between salivary cortisol levels and characteristics of BZD use (duration, dose and severity of BZD dependence as measured by the Bendep-SRQ) among the combined BZD user groups (infrequent and daily). For the duration of use, no effect on any cortisol indicator was found except Cortisol suppression ratio= salivary cortisol T1/salivary cortisol T7, after 0.5 mg dexamethasone. An explanation for the lack of consistent associations could be that BZDs inhibit the HPA axis during short-term use and that tolerance to the cortisol-suppressing effect of BZDs develops after long-term BZD treatment. Correspondingly, intervention studies that found lower cortisol levels in response to BZD administration mainly looked at short-term effects during a time period ranging from 1 day to 1 month, 3, 5, 6, 9, 13, [34] [35] [36] [37] except for a few studies with a duration of 2-3 months. 1, 2, 4 In contrast, chronic users were found to have similar baseline cortisol levels as nonusers, also indicating that BZDs do not maintain their cortisolsuppressing effects in long-term use. 20 As our study mainly consists of chronic users (3-year median duration of use), the lack of association between BZD use and baseline cortisol levels agrees with results from the latter study. 20 Although tolerance is likely to develop during long-term use, an additional dosage of BZDs (on top of a regular daily dosage) still induces HPA axis inhibition. Indeed, Cowley et al. 20 found that long-term users showed similar decreases in plasma cortisol after an extra dosage of BZDs as treatment-naïve patients. 20 In related research on the therapeutic LONG-TERM BENZODIAZEPINE USE AND SALIVARY CORTISOL: THE NETHERLANDS STUDY OF DEPRESSION AND ANXIETY (NESDA) | 151 effects of BZDs, an increased dosage of BZDs was found to increase anxiolytic effects even after more than 10 years of daily use. 38 Along with the hypothesis of tolerance development to the cortisol suppressing effects of long-term BZD use, there are several alternative explanations that may account for discrepancies in findings. First, BZD users may have had enhanced HPA axis activity prior to the start of BZD treatment which was subsequently normalized by long-term BZD treatment. Indeed, a significantly higher percentage of daily users compared to nonusers had comorbid disorder, which has been found to be associated with increased cortisol levels in this study population. 28 Second, it might be that the joint investigation of a number of different types of BZDs with possibly opposing effects on the HPA axis has covered effects on cortisol levels. 39 We found lower diurnal slope levels and a decreased dexamethasone suppression ratio in the diazepam group and a lower AUCg in the alprazolam group compared to the oxazepam group.
characteristics of BZD Use
This may be evidence for the possibly opposing effects of the different
BZDs. This corresponds to a former study that reported BZDs to have either a stimulating or an inhibiting effect on the HPA axis conditional on the alpha subunit of the GABA receptor modulated by the drugs. 39 However, as comparison groups were small in NESDA, results have to be replicated in future research. Third, stronger effects on cortisol levels may be due to higher dosages. In intervention studies higher average dosages were used than in the current study (ie, 12 mg of diazepam equivalents in intervention studies versus 6 mg in NESDA). Another explanation for basal cortisol being the only cortisol measurement differing significantly between BZD user groups might be that hippocampal mineralocorticoid receptors (MRs) are more affected by central acting BZDs than glucocorticoid receptors (GRs). Because MRs are more occupied at intermediate cortisol concentrations while GRs are not, 40 basal evening cortisol might be a probe of MR activity. 41 However, because research on GR, MR and BZDs is still limited, this assumption deserves further confirmation in future research.
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Our study has some limitations. A cross-sectional analysis was done, which precludes causal inferences or differentiation between the potential explanations of the lack of group differences in salivary cortisol. Because we had to rely on subjects' self-report on BZD intake, we cannot be completely sure whether subjects were actually using the medications as prescribed and as they themselves indicated. Noncompliance with instructions of saliva collection due to the ambulatory setting could have resulted in measurement error. In addition, because time of drug intake was not recorded, acute effects of BZD use could not be assessed. Despite these limitations, our study had many strong aspects, 
